Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Cosmetic Raw Material
Pharmaceutical
OEM & ODM
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales28@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Dabigatran Etexilate Mesylate Raw Materials powder
Product Overview:
Dabigatrun mesylate is a direct thrombin inhibitor and a new oral anticoagulant. The mechanism of its action is to inhibit the formation of thrombin by reversibly competing fibrin-specific binding sites that bind thrombin, thereby inhibiting the formation of thrombin.
Dabigatran Etexilate Mesylate Raw Materials powder Attributes
CAS:872728-81-9
MF:C35H45N7O8S
MW:723.85
EINECS:828-727-6
Specification: 99% min Dabigatran Etexilate Mesylate powder
Sample:Dabigatran Etexilate Mesylate powder
Packaging:1kg/bag, 25kg/drum
Brand: Henrikang
Appearance:white
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
Dabigatran Etexilate Mesylate Raw Materials powder Details
Dabigatran Etexilate Mesylate powder Usage and Synthesis.
Dabigatran mesylate is a precursor drug of Dabigatran, which is metabolized in the body and converted into active Dabigatran. Compared with warfarin, dabigatranate mesylate does not require frequent monitoring of coagulation function and adjustment of dosage during treatment, has fewer interactions between drugs, and is not affected by eating, thus improving patient medication compliance.
Dabigatran mesylate is a raw material for blood system. Anticoagulant drugs; It can be used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. dabigatran is a novel synthetic direct thrombin inhibitor, a precursor of Dabigatran and a non-peptide thrombin inhibitor.
Drug interaction of Dabigatran Etexilate Mesylate.
1. Simultaneous use of this product with powerful P-glycoprotein-inducing drugs (such as rifampicin) leads to reduced systemic exposure to this product.
2, this product combined with P-glycoprotein inhibitor, peak time, terminal t1: and the average retention time are not affected. Combined with dronedalone, ketoconazole verapamil, amiodarone and quinidine, the total body exposure of this product increased; Combined with clindamycin has no effect on exposure.
3. Close monitoring of bleeding is recommended when this product is used with NSAIDS drugs for 11>12h
4. It is not recommended that this product be combined with the following drugs (such as ordinary heparin and heparin derivatives for intravenous use, low molecular weight heparin, sulfodaparin sodium, desiludine thrombolysis agent, platelet glycoprotein Ⅱb/Ⅲa receptor inhibitor, clopidogrel, ticlopidine, dextrose anhydride, sulfopyrone, vitamin K antagonist).
Pharmacological action of Dabigatran Etexilate Mesylate.
Product method of Bulk Dabigatran Etexilate Mesylate.